AUPH
Aurinia Pharmaceuticals Inc.
Set alert
16.65 USD -0.56 -3.25%
16.48 Day range 17.04
12.12 52-week range 18.62
- YTD
- +4.39%
- 1 year
- +37.38%
- Open
- 16.76
- Prev close
- 17.21
- Mkt cap
- 2.22B
- Vol
- 960.84K
- Avg vol
- 925.57K
- EPS
- 2.28
- P/E
- 7.30
- Div yield
- 0.00%
More statistics
- Low
- 16.48
- High
- 17.04
- Forward P/E
- 14.26
- Beta
- 1.61
- Short ratio
- 8.95
- Inst. own
- 60.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 4, 2027
- 50-d avg
- 16.50
- 200-d avg
- 15.64
- 1y target
- 18.00
Key statistics
- Market cap
- 2.22B
- Enterprise value
- 1.91B
- Trailing P/E
- 7.30
- Forward P/E
- 14.26
- PEG ratio
- 0.00
- Price / sales
- 7.11
- Price / book
- 3.60
- EPS (TTM)
- 2.28
- Beta
- 1.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 100.84%
- Revenue (TTM)
- 311.51M
- Revenue growth
- 18.90%
- Free cash flow
- 147.82M
- Total cash
- 443.02M
- Total debt
- 64.14M
- Return on equity
- 66.12%
- Shares outstanding
- 133.05M
- Short % of float
- 6.46%
- 50-day average
- 16.50
- 200-day average
- 15.64
Analyst view
Consensus: buy
Buy
Price target (mean) 18.00 +8.1% upside
Now 16.65
- Target (low)
- 16.00
- Target (mean)
- 18.00
- Target (high)
- 21.00
Ratings (0m) 7 5 buy · 2 hold · 0 sell
- Strong buy0
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Mar 4, 2027
Expected Mar 4, 2027. Consensus EPS estimate 0.22.
Financials — quick view
AUPH Revenue — quarterly 83.22M
AUPH Net income — quarterly 37.41M
AUPH EPS — quarterly 0.29
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 4, 2027 | Dec 30, 2026 | 0.214 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | 0.22 | 0.23 | +0.01 | +4.55% |
| Aug 6, 2026 | Jun 30, 2026 | 0.24 | 0.28 | +0.04 | +16.67% |
| May 7, 2026 | Mar 31, 2026 | 0.18 | 0.25 | +0.07 | +38.89% |
| Feb 26, 2026 | Dec 31, 2025 | 0.21 | 0.26 | +0.05 | +23.81% |
| Nov 4, 2025 | Sep 30, 2025 | 0.16 | 0.23 | +0.07 | +43.75% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | TD Cowen | main | Buy | Buy |
| Aug 7, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Dec 3, 2025 | Leerink Partners | down | Outperform | Market Perform |
| Nov 7, 2025 | Jefferies | up | Hold | Buy |
| Nov 5, 2025 | RBC Capital | down | Outperform | Sector Perform |
| Aug 1, 2025 | RBC Capital | main | Outperform | Outperform |
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- auriniapharma.com
News
- Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
- Aurinia Pharmaceuticals Raises FY2026 Sales Guidance from $315.000M-$325.000M to $325.000M-$330.000M vs $330.261M Est
- Aurinia Pharmaceuticals Q3 EPS $0.23 Beats $0.22 Estimate, Sales $83.699M Beat $83.691M Estimate
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
- Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
- Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term
- Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term
- TD Cowen Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $18
- Critical Review: Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Madrigal Pharmaceuticals (NASDAQ:MDGL)
- Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
Your note
Sign in to keep a note on AUPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Aurinia Pharmaceuticals | Issuer | Redemption, retraction, cancelation, repurchase | May 7, 2026 | 56,531 |
| Bailey (Jeffrey Allen) | Director of Issuer | Exercise of rights | Nov 20, 2025 | 22,775 |
| Donley (Matthew Maxwell) | Senior Officer of Issuer | Exercise of rights | Mar 1, 2026 | 440,053 |
| Greenleaf (Peter S) | Director of Issuer | Exercise of rights | Mar 1, 2026 | 1,050,043 |
| Johnson (Craig A) | Director of Issuer | Exercise of rights | Nov 20, 2025 | 14,592 |
| Keenan (Gregory M.D.) | Senior Officer of Issuer | Exercise of rights | Mar 5, 2026 | 28,532 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tang Capital Management, LLC | 9.80% | 13,044,106 | 217.18M | Jun 29, 2026 |
| Blackrock Inc. | 6.16% | 8,193,085 | 136.41M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 4.22% | 5,619,401 | 93.56M | Jun 29, 2026 |
| NEA Management Company, LLC | 2.98% | 3,969,834 | 66.10M | Jun 29, 2026 |
| Two Sigma Investments, LP | 2.61% | 3,467,514 | 57.73M | Jun 29, 2026 |
| Arrowstreet Capital, Limited Partnership | 2.45% | 3,264,062 | 54.35M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Russell 2000 ETF | 2.32% | 3,089,770 | 51.44M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.98% | 1,303,109 | 21.70M | Jul 30, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.84% | 1,116,707 | 18.59M | Sep 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.69% | 917,683 | 15.28M | Sep 29, 2026 |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 0.46% | 613,258 | 10.21M | May 30, 2026 |
| Goldman Sachs Trust-Goldman Sachs U.S. Tax-Managed Equity Fund | 0.41% | 541,443 | 9.02M | Jun 29, 2026 |